REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO (Nasdaq: RGNX) has announced its participation in three major healthcare investor conferences in late 2024. The company will present at the UBS Global Healthcare Conference on November 13 in Rancho Palos Verdes, the Stifel Healthcare Conference on November 19 in New York, and the Piper Sandler Annual Healthcare Conference on December 5 in New York. All presentations will be available via live webcast through REGENXBIO's website, with recordings accessible for approximately 30 days after each event.
REGENXBIO (Nasdaq: RGNX) ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario alla fine del 2024. L'azienda presenterà alla Conferenza Sanitaria Globale UBS il 13 novembre a Rancho Palos Verdes, alla Conferenza Sanitaria Stifel il 19 novembre a New York e alla Conferenza Sanitaria Annuale Piper Sandler il 5 dicembre a New York. Tutte le presentazioni saranno disponibili tramite webcast dal vivo attraverso il sito web di REGENXBIO, con registrazioni accessibili per circa 30 giorni dopo ciascun evento.
REGENXBIO (Nasdaq: RGNX) ha anunciado su participación en tres importantes conferencias de inversión en el sector salud a finales de 2024. La compañía presentará en la Conferencia Global de Salud de UBS el 13 de noviembre en Rancho Palos Verdes, en la Conferencia de Salud de Stifel el 19 de noviembre en Nueva York, y en la Conferencia Anual de Salud de Piper Sandler el 5 de diciembre en Nueva York. Todas las presentaciones estarán disponibles a través de transmisión en vivo por el sitio web de REGENXBIO, con grabaciones accesibles durante aproximadamente 30 días después de cada evento.
REGENXBIO (Nasdaq: RGNX)는 2024년 말에 열리는 세 가지 주요 의료 투자 콘퍼런스에 참여할 것이라고 발표했습니다. 회사는 11월 13일 랜초 팔로스 베르데스에서 열리는 UBS 글로벌 헬스케어 콘퍼런스, 11월 19일 뉴욕에서 열리는 스티펠 헬스케어 콘퍼런스, 그리고 12월 5일 뉴욕에서 열리는 파이퍼 샌들러 연례 헬스케어 콘퍼런스에서 발표할 예정입니다. 모든 발표는 REGENXBIO 웹사이트를 통해 실시간으로 웹캐스트로 제공되며, 각 이벤트 후 약 30일 동안 녹화가 접근 가능합니다.
REGENXBIO (Nasdaq: RGNX) a annoncé sa participation à trois grandes conférences d'investisseurs en soins de santé à la fin de 2024. La société fera une présentation lors de la Conférence Mondiale sur la Santé UBS le 13 novembre à Rancho Palos Verdes, de la Conférence sur la Santé Stifel le 19 novembre à New York et de la Conférence Annuelle sur la Santé Piper Sandler le 5 décembre à New York. Toutes les présentations seront disponibles par webcast en direct via le site web de REGENXBIO, avec des enregistrements accessibles pendant environ 30 jours après chaque événement.
REGENXBIO (Nasdaq: RGNX) hat seine Teilnahme an drei bedeutenden Investorenkonferenzen im Gesundheitswesen Ende 2024 bekannt gegeben. Das Unternehmen wird am 13. November auf der UBS Global Healthcare Conference in Rancho Palos Verdes, am 19. November auf der Stifel Healthcare Conference in New York und am 5. Dezember auf der Piper Sandler Annual Healthcare Conference in New York präsentieren. Alle Präsentationen werden über einen Live-Webcast auf der Website von REGENXBIO verfügbar sein, wobei die Aufzeichnungen etwa 30 Tage lang nach jeder Veranstaltung zugänglich sind.
- None.
- None.
UBS Global Healthcare Conference
Fireside Chat: Wednesday, November 13 at 12:30 p.m. PT
Location:
Stifel 2024 Healthcare Conference
Fireside Chat: Tuesday, November 19 at 11:30 a.m. ET
Location:
Piper Sandler 36th Annual Healthcare Conference
Fireside Chat: Thursday, December 5 at 9:30 a.m. ET
Location:
Live webcasts of the fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302294648.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) presenting at the UBS Global Healthcare Conference 2024?
How can I watch REGENXBIO's (RGNX) investor conference presentations in November-December 2024?
Which investor conferences is REGENXBIO (RGNX) attending in late 2024?
